Intuitive Surgical Shares Plunge: Why Analysts Reset Price Targets

Intuitive Surgical (ISRG) shares are under heavy selling pressure after a full‑year outlook that fell short of expectations following the quarterly results.

Cooling Growth Outlook

The company disclosed that da Vinci procedure growth will taper to 14.5% this year – the exact midpoint of its prior guidance range – prompting investors to lower their forecasts.

Revised Analyst Targets

■Citi: Target $500, “Buy” rating.

■JPMorgan: Target $450.

■Mizuho: Target $400, “Hold” rating.

■Bernstein: Target $685 (down from $750), “Outperform” rating.

Technical Indicators & Volume

The stock’s Relative Strength Index (RSI) slipped into the early 30s, edging into oversold territory and hinting at a possible short‑term relief rally.

Key Risk Factors

■Changes to the U.S. Affordable Care Act could curb elective procedure volumes.

■Da Vinci procedure growth slowing to 14.5%, potentially limiting demand for instruments and accessories.

■Global procedures grew 16% YoY, but regional regulatory headwinds may erode this momentum.

■Growing investor caution around price‑to‑earnings multiples.

Markets are reacting cautiously to ISRG’s solid quarterly performance but muted guidance. While the technical oversold signal may spark a near‑term bounce, regulatory uncertainties and the slowdown in procedure growth are likely to cap medium‑term upside. A valuation range of $450‑$500 appears to reflect a fair price for the stock.